Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adc Therapeutics Sa (NY: ADCT )

4.780 -0.190 (-3.82%)
Official Closing Price Updated: 4:00 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adc Therapeutics Sa

< Previous 1 2 3 4 5 6 7 Next >
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
A Preview Of ADC Therapeutics's Earnings
Via Benzinga
ADC Therapeutics - Time For A Turn-Around?
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. 
Via Talk Markets
Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On Wednesday
U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
From ADC Therapeutics SA
Via GlobeNewswire
Analyst Expectations for ADC Therapeutics's Future
Via Benzinga
The Latest Analyst Ratings for ADC Therapeutics
Via Benzinga
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
From ADC Therapeutics SA
Via GlobeNewswire
Alaska Air To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider. 
Via InvestorPlace
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger... 
Via Benzinga
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Participate in September Investor Conferences
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
From ADC Therapeutics SA
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Via Benzinga
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.